Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Free Cash Flow (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Free Cash Flow for 6 consecutive years, with -$12.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 14.4% year-over-year to -$12.8 million, compared with a TTM value of -$37.9 million through Sep 2025, up 34.5%, and an annual FY2024 reading of -$56.1 million, down 22.41% over the prior year.
  • Free Cash Flow was -$12.8 million for Q3 2025 at Ovid Therapeutics, down from -$4.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $160.9 million in Q1 2021 and bottomed at -$20.1 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$3.6 million, with a median of -$12.1 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 972.07% in 2021, while the deepest fall reached 630.04% in 2021.
  • Year by year, Free Cash Flow stood at -$12.2 million in 2021, then grew by 16.66% to -$10.1 million in 2022, then decreased by 16.67% to -$11.8 million in 2023, then increased by 15.33% to -$10.0 million in 2024, then decreased by 28.13% to -$12.8 million in 2025.
  • Business Quant data shows Free Cash Flow for OVID at -$12.8 million in Q3 2025, -$4.8 million in Q2 2025, and -$10.3 million in Q1 2025.